Abstract:Macrophages are important effector cells in inflammatory responses. They are involved in bacterial infections and autoimmune diseases but also in the low grade inflammation associated with obesity and metabolic syndrome. Macrophages also have homeostatic functions and they activate healing process associated with inflammation and tissue injury [1-3]. To achieve these multiform tasks, macrophages are programmed to display distinct phenotypes in response to environmental signals [2-5]. For example, Th1 cytokine interferon γ (IFNγ) and toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) trigger classical, i.e. type M1, activation of macrophages, which is typical for bacterial infections and autoimmune reactions [6]. On the other hand, Th2 cytokines interleukin (IL) 4 and 13 trigger alternative, i.e. type M2, activation, which is associated with wound healing but also with the aberrant immune responses associated with overactivation of fibroblasts and subsequent fibrosis [6,7]. Classical activation of macrophages leads to the release of proinflammatory and antimicrobial factors including IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) pathway. On the other hand, alternatively activated macrophages express factors that have been associated with recognition of extracellular pathogens and/or stimulation of fibroblasts. Some of Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with Research Article Open Access

Changes in Macrophage PPAR Gamma Anti-Inflammatory Activities under High Insulin Levels

Insulin promotes macrophage phenotype transition through PI3K/Akt and PPAR‐γ signaling during diabetic wound healing

Effects of Ligand-Activation of Peroxisome Proliferator Activated Receptors-Γ (Ppar-Γ) on Expression of ACAT-1 with High Concentrations of Insulin and Glucose

Pioglitazone Alleviates Inflammation in Diabetic Mice Fed a High‐fat Diet Via Inhibiting Advanced Glycation End‐product‐induced Classical Macrophage Activation

Effects of insulin on macrophage phenotype transformation under high glucose condition

Pioglitazone Suppresses the Lipopolysaccharide-Induced Production of Inflammatory Factors in Mouse Macrophages by Inactivating Nf-Kappa B

Inhibitory Effect of Peroxisome Proliferator Activated Receptor γ Ligands on Secretion of Inflammatory Cytokine and Matrix Metalloproteinase in Macrophages and Foam Cell

Effect of PPAR Ligands on Extracellular Matrix Metalloproteinase Inducer Expression in Macrophages and Foam Cells

The inhibitory effect of troglitazone on macrophage differentiation mediated by repressing NF-κB ctivation independently of PPARγ

Effects of pioglitazone on the expressions of p38 mitogen-activated protein kinase and transforming growth factor β-1 in cultured rat glomerular mesangial cells

Anti-Inflammatory Effect Of Ppar Gamma In Cultured Human Mesangial Cells

Temporal Effects Of Peroxisome Proliferator-Activated Receptor. Activation On Macrophage Inflammatory Responses

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

[The Relationship Between Islet Alpha Cell Insulin Resistance and Inflammatory Pathway Activation and Its Mechanism].

[Effects of mice macrophages on skeletal muscle cells under high glucose treatment]

Panax notoginseng Saponins Regulate Macrophage Polarization under Hyperglycemic Condition via NF- κ B Signaling Pathway

Interactions between myoblasts and macrophages under high glucose milieus result in inflammatory response and impaired insulin sensitivity

Insulin Influences LPS-Induced TNF-α and IL-6 Release Through Distinct Pathways in Mouse Macrophages from Different Compartments

Effect and Mechanism of Insulin on the Expression of Toll-Like Receptor4 in Macrophage-drived Foam Cells

High Glucose Increases the Expression of Inflammatory Cytokine Genes in Macrophages Through H3K9 Methyltransferase Mechanism.

Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus